Dall'Igna P, et al. - This research intended to examine the clinical characteristics, treatment, and survival of children, who were diagnosed with hepatoblastoma (HB) in their first 6 months of age. A similarity was noted in the 5-year overall survival (OS) and event-free survival (EFS) of children <6 months of age affected by HB with those documented in the elder children. Dose reduction did not possibly jeopardize the long-term outcome. It could elucidate the lower toxicity profile. Ototoxicity was found to be as high as in the whole population of SIOPEL 2 and 3. The therapeutic aspects emphasizing on the prevention of hearing loss warranted advanced research.